{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:17:25Z","timestamp":1769307445596,"version":"3.49.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/hco.0000000000000036","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T11:05:37Z","timestamp":1389265537000},"page":"160-166","source":"Crossref","is-referenced-by-count":32,"title":["Brain natriuretic peptide"],"prefix":"10.1097","volume":"29","author":[{"given":"Gnanadevan","family":"Mahadavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.36.3.355","article-title":"Deconvolution analysis of cardiac natriuretic peptides during acute volume overload.","volume":"36","author":"Pemberton","year":"2000","journal-title":"Hypertension"},{"key":"R2-8-20210204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/paa.1999.111.5.406","article-title":"The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.","volume":"111","author":"Chen","year":"1999","journal-title":"Proc Assoc Am Phys"},{"key":"R3-8-20210204","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","article-title":"Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure.","volume":"87","author":"Yoshimura","year":"1993","journal-title":"Circulation"},{"key":"R4-8-20210204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2310\/JIM.0b013e3181948b37","article-title":"Cardiac natriuretic peptides gene expression and secretion in inflammation.","volume":"57","author":"de Bold","year":"2009","journal-title":"J Investig Med"},{"key":"R6-8-20210204","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00005344-200402000-00010","article-title":"The role of endothelin in mediating ischemiahypoxia-induced atrial natriuretic peptide release.","volume":"43","author":"Zhang","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R7-8-20210204","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/cc9398","article-title":"Direct comparison of serial B-type natriuretic peptide and NT-Pro BNP levels for prediction of short- and long-term outcome in acute decompensated heart failure.","volume":"15","author":"Noveanu","year":"2011","journal-title":"Crit Care"},{"key":"R8-8-20210204","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jacc.2006.12.013","article-title":"Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!.","volume":"49","author":"Chen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R9-8-20210204","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCHEARTFAILURE.108.790774","article-title":"Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.","volume":"1","author":"Niederkofler","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R10-8-20210204","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jacc.2006.12.024","article-title":"Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.","volume":"49","author":"Lam","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R11-8-20210204","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jacc.2006.08.066","article-title":"Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.","volume":"49","author":"Forfia","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R12-8-20210204","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-8-20210204","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2004.06.015","article-title":"Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.","volume":"44","author":"Maisel","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R14-8-20210204","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ahj.2005.10.017","article-title":"Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study.","volume":"151","author":"Brenden","year":"2006","journal-title":"Am Heart J"},{"key":"R15-8-20210204","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejheart.2004.12.006","article-title":"Predischarge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit.","volume":"7","author":"Verdiani","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"R16-8-20210204","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/01.CIR.0000016642.15031.34","article-title":"B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.","volume":"105","author":"Berger","year":"2002","journal-title":"Circulation"},{"key":"R17-8-20210204","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2003.09.044","article-title":"Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.","volume":"43","author":"Logeart","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R18-8-20210204","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/01.CIR.0000143059.68996.A7","article-title":"Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.","volume":"110","author":"Hartmann","year":"2004","journal-title":"Circulation"},{"key":"R19-8-20210204","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.hlc.2013.03.077","article-title":"B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.","volume":"10","author":"Li","year":"2013","journal-title":"Heart Lung Circ"},{"key":"R20-8-20210204","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","article-title":"Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality) study.","volume":"56","author":"Eurlings","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R21-8-20210204","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.","volume":"58","author":"Januzzi","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R22-8-20210204","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","article-title":"The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.","volume":"17","author":"Shah","year":"2011","journal-title":"J Card Fail"},{"key":"R23-8-20210204","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurjhf\/hfr078","article-title":"Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.","volume":"13","author":"Karlstrom","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"R24-8-20210204","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejheart.2003.10.003","article-title":"N-terminal pro-brain natriuretic peptide for discriminating between cardiac and noncardiac dyspnoea.","volume":"6","author":"Nielsen","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"R25-8-20210204","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2007.02.037","article-title":"Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.","volume":"49","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R26-8-20210204","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0735-1097(01)01269-4","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.","volume":"37","author":"Richards","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R27-8-20210204","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R28-8-20210204","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"R29-8-20210204","first-page":"237","article-title":"Tako-Tsubo cardiomyopathy: NT-Pro BNP as a reliable parameter of a favourable prognosis Int J C","volume":"124","author":"Nef","year":"2008","journal-title":"ardiol"},{"key":"R30-8-20210204","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijcard.2006.12.085","article-title":"Increased B-type natriuretic peptide levels in patients with apical ballooning syndrome: consecutive cases report.","volume":"124","author":"Grabowski","year":"2008","journal-title":"Int J Cardiol"},{"key":"R31-8-20210204","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/hrt.2009.170399","article-title":"Stress hormone and circulating biomarker profile of apical ballooning syndrome (Tako-Tsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels.","volume":"95","author":"Madhavan","year":"2009","journal-title":"Heart"},{"key":"R32-8-20210204","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cardfail.2008.10.031","article-title":"Importance of inflammation and neurohumoral activation in Tako-Tsubo cardiomyopathy.","volume":"15","author":"Morel","year":"2009","journal-title":"J Card Fail"},{"key":"R33-8-20210204","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MCA.0b013e3283526a57","article-title":"Brain natriuretic peptide in apical ballooning syndrome (Tako-Tsubostress cardiomyopathy): comparison with acute myocardial infarction.","volume":"23","author":"Ahmed","year":"2012","journal-title":"Coron Artery Dis"},{"key":"R34-8-20210204","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.amjcard.2011.06.047","article-title":"N-terminal pro-brain natriuretic protein levels in Tako-Tsubo cardiomyopathy.","volume":"108","author":"Nguyen","year":"2011","journal-title":"Am J Cardiol"},{"key":"R35-8-20210204","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"R36-8-20210204","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1378\/chest.12-0270","article-title":"Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.","volume":"143","author":"Fritz","year":"2013","journal-title":"Chest"},{"key":"R37-8-20210204","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy.","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R38-8-20210204","first-page":"331","article-title":"Natriuretic peptides and long-term mortality in patients with severe aortic stenosis.","volume":"21","author":"Katz","year":"2012","journal-title":"J Heart Valve Dis"},{"key":"R39-8-20210204","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ejechocard\/jer120","article-title":"Impact of aortic stiffness on left ventricular function and B-type natriuretic peptide release in severe aortic stenosis.","volume":"12","author":"Rosca","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"R40-8-20210204","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/heartjnl-2012-303284","article-title":"Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study.","volume":"99","author":"Cimadevilla","year":"2013","journal-title":"Heart"},{"key":"R41-8-20210204","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.amjcard.2013.04.023","article-title":"Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis.","volume":"112","author":"Ben-Dor","year":"2013","journal-title":"Am J Cardiol"},{"key":"R42-8-20210204","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"key":"R43-8-20210204","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e31829d8773","article-title":"High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke.","volume":"81","author":"Rodriguez-Yanez","year":"2013","journal-title":"Neurology"},{"key":"R44-8-20210204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-9966-31-13","article-title":"Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.","volume":"31","author":"Roziakova","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"R45-8-20210204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/0044011-200929020-00007","article-title":"Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.","volume":"29","author":"Cil","year":"2009","journal-title":"Clin Drug Investig"},{"key":"R46-8-20210204","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"R47-8-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(97)03034-1","article-title":"Biochemical detection of left-ventricular systolic dysfunction.","volume":"351","author":"McDonagh","year":"1998","journal-title":"Lancet"},{"key":"R48-8-20210204","first-page":"647","article-title":"Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction in Portuguese.","volume":"32","author":"Lagoeiro","year":"2013","journal-title":"Rev Port Cardiol"},{"key":"R49-8-20210204","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.","volume":"110","author":"Anjan","year":"2014","journal-title":"Am J Cardiol"},{"key":"R50-8-20210204","first-page":"281","article-title":"Can natriuretic peptides be used for the diagnosis of diastolic heart failure Eur J Heart F","volume":"6","author":"Dahlstrom","year":"2004","journal-title":"ail"},{"key":"R51-8-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pcad.2005.02.001","article-title":"Neurohumoral pathways in heart failure with preserved systolic function.","volume":"47","author":"Hogg","year":"2005","journal-title":"Prog Cardiovasc Dis"},{"key":"R52-8-20210204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijcard.2011.07.017","article-title":"Combination of B-type natriuretic peptide and minute ventilationcarbon dioxide production slope improves risk stratification in patients with diastolic heart failure.","volume":"162","author":"Yan","year":"2013","journal-title":"Int J Cardiol"},{"key":"R53-8-20210204","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R54-8-20210204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/qjmed\/hcg096","article-title":"The clinical features of Tako-Tsubo cardiomyopathy.","volume":"96","author":"Akashi","year":"2003","journal-title":"QJM"},{"key":"R55-8-20210204","first-page":"216","article-title":"Comparison of the clinical characteristics of apical and nonapical variants of broken heart (Tako-Tsubo) syndrome in the United States.","volume":"21","author":"Jabara","year":"2009","journal-title":"J Invasive Cardiol"},{"key":"R56-8-20210204","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/qjmed\/hch094","article-title":"Plasma brain natriuretic peptide in Tako-Tsubo cardiomyopathy.","volume":"97","author":"Akashi","year":"2004","journal-title":"QJM"},{"key":"R57-8-20210204","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa043046","article-title":"Neurohumoral features of myocardial stunning due to sudden emotional stress.","volume":"352","author":"Wittstein","year":"2005","journal-title":"N Engl J Med"},{"key":"R58-8-20210204","doi-asserted-by":"crossref","first-page":"526e1","DOI":"10.1016\/j.ahj.2007.10.042","article-title":"Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy).","volume":"155","author":"Yoshioka","year":"2008","journal-title":"Am Heart J"},{"key":"R59-8-20210204","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2007.08.102","article-title":"Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance.","volume":"132","author":"Abdel-Aty","year":"2009","journal-title":"Int J Cardiol"},{"key":"R60-8-20210204","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00330-009-1549-5","article-title":"Inflammation in Tako-Tsubo cardiomyopathy: insights from cardiovascular magnetic resonance imaging.","volume":"20","author":"Eitel","year":"2010","journal-title":"Eur Radiol"},{"key":"R61-8-20210204","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/eurheartj\/ehl570","article-title":"Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery.","volume":"28","author":"Nef","year":"2007","journal-title":"Eur Heart J"},{"key":"R62-8-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2007.08.046","article-title":"Hyperintensity on T2-weighted magnetic resonance imaging in Tako-Tsubo cardiomyopathy.","volume":"130","author":"Otsuka","year":"2008","journal-title":"Int J Cardiol"},{"key":"R63-8-20210204","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehp140","article-title":"Immunohistological basis of the late gadolinium enhancement phenomenon in Tako-Tsubo cardiomyopathy.","volume":"30","author":"Rolf","year":"2009","journal-title":"Eur Heart J"},{"key":"R64-8-20210204","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.111.059097","article-title":"An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition.","volume":"125","author":"Chan","year":"2012","journal-title":"Circulation"},{"key":"R65-8-20210204","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","article-title":"N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.","volume":"120","author":"Patton","year":"2009","journal-title":"Circulation"},{"key":"R66-8-20210204","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"R67-8-20210204","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0306-3623(96)00275-3","article-title":"Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds.","volume":"28","author":"Arjona","year":"1997","journal-title":"Gen Pharmacol"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HCO.0000000000000036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:42:49Z","timestamp":1620952969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001573-201403000-00008"}},"subtitle":["a biomarker for all cardiac disease?"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0000000000000036","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}